Besifloxacin Hydrochloride

CHEMBL1201761 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
430.3 g/mol
LogP
Phase
4

The hydrochloride salt of besifloxacin, a topical ophthalmic fluoroquinolone antibiotic used to treat bacterial eye infections. Applied as eye drops, it targets a wide range of bacteria responsible for conjunctivitis. It was specifically developed for ophthalmic use to minimize systemic exposure.

Khối lượng phân tử

430,3000 g/mol

TPSA

86,90 Ų

Cơ chế tác dụng

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cl.N[C@@H]1CCCCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2Cl)C1

InChI

InChI=1S/C19H21ClFN3O3.ClH/c20-15-16-12(18(25)13(19(26)27)9-24(16)11-4-5-11)7-14(21)17(15)23-6-2-1-3-10(22)8-23;/h7,9-11H,1-6,8,22H2,(H,26,27);1H/t10-;/m1./s1

Molecular Formula

C19H22Cl2FN3O3

HBD / HBA

3 / 7

Liên kết có thể quay

3

Nguyên tử nặng

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

The hydrochloride salt of besifloxacin, a topical ophthalmic fluoroquinolone antibiotic used to treat bacterial eye infections. Applied as eye drops, it targets a wide range of bacteria responsible for conjunctivitis. It was specifically developed for ophthalmic use to minimize systemic exposure.

Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.

Yes, Besifloxacin Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201761. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 10224595. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.